In male patients with de novo stage IV breast cancer who were ER+ or PR+, it was discovered that those who received surgery, radiation therapy, and systemic therapy (trimodality) had a significant survival advantage over those who received only systemic therapy. Here, ESR1 is linked to breast cancer.